熱景生物(688068.SH):新冠抗原檢測試劑(唾液)獲得德國聯邦藥品和醫療器械研究所(Bfarm)認證延期至9月20日
格隆匯6月24日丨熱景生物(688068.SH)公佈,公司於2021年3月22日經德國聯邦藥品和醫療器械研究所(Bfarm)特殊批准的新冠抗原檢測試劑(唾液)的有效期,於近日獲得暫時延長至2021年9月20日,有效期3個月。截止公吿披露日,公司德國產品的大額訂單已交付完畢;後續能否繼續獲得大的訂單存在較大的不確定性。
德國新冠快速檢測產品市場競爭激烈,需求量持續下降。截止2021年6月24日,全球已有76款產品獲批進入德國家庭自測市場,較3月22日公司兩款自檢產品獲批進入德國家庭自測市場時候,德國家庭自測市場的競爭環境已經發生很大的變化,競爭日趨激勵,競爭者的增加也逐步擠佔了公司的市場份額;同時,隨着德國疫苗接種計劃等傳染病防治計劃的推行,德國各州新冠感染指數也逐步下降,產品需求量也持續下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.